Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 2.

Autophagy inhibitors for treating cancer

Compound Target or mode of action Cancer types References
3-Methyladenine (3-MA), LY294002 Class III PI3K HeLa cells Hou et al., 2012
Bafilomycin A1 Beclin-1, lysosomal H+-ATPase inhibitor Gastric cancer cells Li et al., 2016
Chloroquine (CQ) Fusion process of autophagosome and lysosome Glioma cells, breast cancer, colon cancer Hori et al., 2015; Cave et al., 2018; Liu et al., 2019
Hydroxychloroquine (HCQ) Lysosomal capthepsin D Colorectal cancer, breast cancer Cook et al., 2014; Patel et al., 2016
Quinacrine p21/p27 Ovarian cancer Jung et al., 2018
ABT-737 Bcl-2 Multiple myeoloma, colorectal cancer cells Sun et al., 2018
Obatoclax Bcl-2 Bladder cancer, colorectal cancer Koehler et al., 2015; Jimenez-Guerrero et al., 2018
Bortezomib Proteasome Multiple myeloma, prostate cancer cells, osteocarcinoma, breast cancer cells, ovarian cancer cells, glioblastoma Periyasamy-Thandavan et al., 2010; Zhu et al., 2010; Lou et al., 2013; Kao et al., 2014; Zhang et al., 2014
Elaiophylin Inhibition of autophagy flux Ovarian cancer cells, multiple myeloma Zhao et al., 2015; Wang et al., 2017
4-Acetylantroquinonol B Inhibition of autophagy flux Epithelial cancer cells Liu et al., 2017
Thymoquinone Permeabilization of the lysosome membrane Glioblastoma cells Racoma et al., 2013
Biomolecules & Therapeutics 2020;28:503~511 https://doi.org/10.4062/biomolther.2020.155
© Biomolecules & Therapeutics